Cart
sales@molnova.com
Oglemilast
CAS No. 778576-62-8
Oglemilast( GRC 3886 )
Catalog No. M15938 CAS No. 778576-62-8
Oglemilast (GRC-3886) is a potent and selective PDE4 inhibitor with IC50 of 2.5 and 1.7 nM for PDE4B and PDE4D, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 29 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 75 | In Stock |
|
| 25MG | 130 | In Stock |
|
| 50MG | 166 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOglemilast
-
NoteResearch use only, not for human use.
-
Brief DescriptionOglemilast (GRC-3886) is a potent and selective PDE4 inhibitor with IC50 of 2.5 and 1.7 nM for PDE4B and PDE4D, respectively.
-
DescriptionOglemilast (GRC-3886) is a potent and selective PDE4 inhibitor with IC50 of 2.5 and 1.7 nM for PDE4B and PDE4D, respectively.Asthma Phase 1 Discontinued.
-
In VitroOglemilast (GRC 3886) has EC50s of 11.4 nM, 4.4 nM for PDE 4B1 and PDE 4D3 reporter cell lines, respectively.
-
In Vivo——
-
SynonymsGRC 3886
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationAsthma
Chemical Information
-
CAS Number778576-62-8
-
Formula Weight516.297
-
Molecular FormulaC20H13Cl2F2N3O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 4 mg/mL7.75 mM;H2O : < 0.1 mg/mL
-
SMILESO=C(C1=C2C(OC3=CC=C(NS(=O)(C)=O)C=C23)=C(OC(F)F)C=C1)NC4=C(Cl)C=NC=C4Cl
-
Chemical NameN-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Giembycz MA. Br J Pharmacol. 2008 Oct;155(3):288-90.
molnova catalog
related products
-
LJI308
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
-
ONO-6126
ONO-6126 is a potent and selective PDE4 inhibitor for the treatment of bronchial asthma and allergic conjunctivitis.
